tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Travere Therapeutics falls -31.7%
PremiumThe FlyTravere Therapeutics falls -31.7%
3h ago
Midday Fly By: JPMorgan reports mixed Q4, L3Harris to form new missile company
Premium
The Fly
Midday Fly By: JPMorgan reports mixed Q4, L3Harris to form new missile company
3h ago
Travere Therapeutics falls -24.3%
Premium
The Fly
Travere Therapeutics falls -24.3%
5h ago
Travere Therapeutics rises 13.2%
PremiumThe FlyTravere Therapeutics rises 13.2%
20d ago
Promising Outlook for Travere Therapeutics: Buy Rating Affirmed on Anticipated FILSPARI Approval and Strategic Initiatives
Premium
Ratings
Promising Outlook for Travere Therapeutics: Buy Rating Affirmed on Anticipated FILSPARI Approval and Strategic Initiatives
29d ago
Ligand initiated with a Buy at Citi
Premium
The Fly
Ligand initiated with a Buy at Citi
1M ago
Travere Therapeutics price target raised to $35 from $26 at Piper Sandler
PremiumThe FlyTravere Therapeutics price target raised to $35 from $26 at Piper Sandler
2M ago
Promising Outlook for Travere Therapeutics: Buy Rating Affirmed on Strong Product Demand and Strategic Growth Potential
Premium
Ratings
Promising Outlook for Travere Therapeutics: Buy Rating Affirmed on Strong Product Demand and Strategic Growth Potential
2M ago
Travere Therapeutics’ Strong Quarter and Future Prospects
Premium
Company Announcements
Travere Therapeutics’ Strong Quarter and Future Prospects
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100